OTCMKTS:AMBS Amarantus Bioscience (AMBS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Amarantus Bioscience Stock (OTCMKTS:AMBS) Get Amarantus Bioscience alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume753 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Amarantus Bioscience Holdings, Inc. is a development‐stage biotechnology company focused on the discovery and development of diagnostic and therapeutic products for neurodegenerative diseases. The company’s pipeline includes Eltoprazine, a serotonergic agent in clinical trials for the treatment of levodopa‐induced dyskinesia in Parkinson’s disease, and recombinant human mesencephalic astrocyte‐derived neurotrophic factor (MANF) for potential applications in neuroprotection. Leveraging both small molecule and biologic platforms, Amarantus aims to address unmet medical needs in Parkinson’s disease, Alzheimer’s disease and traumatic brain injury. In addition to its therapeutic programs, Amarantus operates a diagnostics division dedicated to the identification of biomarkers for central nervous system injuries and mild cognitive impairment. The company’s diagnostic initiatives include blood‐based assays and imaging approaches designed to support early detection, patient stratification and treatment monitoring. These tools are intended to complement its drug development activities and facilitate clinical decision‐making in both neurology and sports medicine. Headquartered in Emeryville, California, Amarantus conducts clinical trials and research collaborations across North America and Europe. The company is led by a management team with deep expertise in drug development, regulatory strategy and commercialization. Steven C. Quay, MD, PhD, serves as chairman, guiding corporate strategy while the senior leadership focuses on advancing the pipeline toward regulatory milestones and potential partnerships.AI Generated. May Contain Errors. Read More Receive AMBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarantus Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMBS Stock News HeadlinesAmarantus Bioscience Holdings Inc (AMBS)October 31, 2024 | investing.comEnsysce Biosciences, Inc. Common Stock (ENSC)April 27, 2024 | nasdaq.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.October 23 at 2:00 AM | Banyan Hill Publishing (Ad)Amarantus BioScience Holdings, Inc. (AMBS)April 1, 2024 | finance.yahoo.comAmarantus BioScience Holdings Inc.January 23, 2024 | wsj.comAmarantus Bioscience Holdings Inc AMBSNovember 10, 2023 | morningstar.comMIndiana University To Invest $250 Million In Bioscience And Technology InitiativesNovember 5, 2023 | forbes.comJord BioScience Announces Keri Carstens as Chief Executive OfficerFebruary 23, 2023 | benzinga.comSee More Headlines AMBS Stock Analysis - Frequently Asked Questions How do I buy shares of Amarantus Bioscience? Shares of AMBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarantus Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarantus Bioscience investors own include Aurora Cannabis (ACB), B2Gold (BTG), CEA Industries (CEAD), Fortune Minerals (FTMDF), Kutcho Copper (KCCFF), Liberty Star Uranium & Metals (LBSR) and Liberty Gold (LGDTF). Company Calendar Today10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:AMBS CIK1424812 Webwww.amarantus.com Phone(650) 862-5391Fax408-852-4427Employees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.57 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:AMBS) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarantus Bioscience Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarantus Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.